Sharma will be responsible for leading medical research, translational science and clinical trials for the company’s oncology business. He will report to chief medical officer and senior VP of medical affairs Dee Khuntia.
“Dr. Sharma is an international authority on the multi-modality treatment of cancer with precision radiotherapy as well as on the translation of radiobiology from the laboratory to the clinic,” Khuntia said in a news release. “His experience of leading practice-changing international clinical trials and his well-established track record in taking cancer care innovations from the scientific laboratory to patients in the clinic will be critical in demonstrating a strong evidence base for Varian’s new technologies in the fight against cancer.”
Prior to joining Varian, Sharma was the chair of radiation oncology at the University College London in the U.K. He has also served as the global chief investigator in 15 phase I, II and II clinical trials in radiation, medical and interventional oncology.
“It is an honor to join Varian to spearhead its ongoing efforts to provide the best treatment to patients anywhere in the world,” Sharma said. “I am proud to be part of a company that innovates, supports and simplifies cancer-fighting solutions everywhere to create a world without fear of cancer.”